Redeye is sad to hear that CEO Anders Kottenauer is leaving the company.
Redeye states the Q3 report was strong across the board.
We expect a decent Q3 report on 18 November. We forecast group sales will grow 28% (2 pp organic), u...
Ferronordic's Q3 report was better than we expected, driven by good sales mix in Russia/CIS.
Redeye retains its positive view of CombinedX following a soft Q3 report, hurt by high employee turn...
Redeye endorses today’s news from Heliospectra, an order of USD780,000 from an American AgTech compa...
Learning to Sleep publicerade den 11 november 2022 bolagets delårsrapport för det tredje kvartalet 2...
Supply chain issues and shortages continue to hit Boule Missed sales by 13% and EBIT by 80% vs.
Redeye comments on Mendus’ Q3 2022 report, as the company is approaching a crucial survival readout ...
Prostatype are making good European launch progress with clinical evaluations, ongoing evaluations a...
Redeye comments on Isofol’s Q3 2022 report, and we expect the company to communicate a clearer path ...
Ett svagt kvartal Bolagets nettoomsättning uppgick till 1,0 mkr (3,6 mkr) och rörelseresultatet blev...
Försäljningen i gång på de viktigaste europeiska marknaderna Allt fokus är på lanseringen av hästvac...
Omsättning något över våra estimat Omsättningen uppgick till EUR 12,9m vs våra estimat om EUR 12,3, ...
Development starkt i Q3 medan Production var svagt Arise rapporterade ett starkt Q3'22 med EBIT om 6...
Redey is happy to see Image Systems delivering very strong Q3 numbers, with earnings and margins at ...
Sales SEK 18.8m, -35% vs. ABGSCe SEK 28.9m EBITDA SEK -1.
IFreja’s Q3 report confirmed our positive views and our concerns.
Redeye is pleased that Bioservo’s Carbonhand 2.0 has now been classified and approved as a medical d...
Media and Games Invest’s (MGI’s) recent EGM confirmed that the group can now proceed with its reloca...
